Evelo Biosciences News Releases http://ir.evelobio.com/ Evelo Biosciences News Releases en Evelo Biosciences to Present at Upcoming Investor Conferences in June http://ir.evelobio.com/news-releases/news-release-details/evelo-biosciences-present-upcoming-investor-conferences-june CAMBRIDGE, Mass. , May 30, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with striking therapeutic effects throughout the body, today announced that management will Thu, 30 May 2019 08:00:00 -0400 Evelo Biosciences News Releases 6786 Evelo Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference http://ir.evelobio.com/news-releases/news-release-details/evelo-biosciences-present-2019-rbc-capital-markets-global CAMBRIDGE, Mass. , May 15, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with striking therapeutic effects throughout the body, today announced that management will Wed, 15 May 2019 08:00:00 -0400 Evelo Biosciences News Releases 6781 Evelo Biosciences Reports First Quarter 2019 Financial Results and Recent Business Highlights http://ir.evelobio.com/news-releases/news-release-details/evelo-biosciences-reports-first-quarter-2019-financial-results -- Novel Formulation of Monoclonal Microbials Discovered, Preclinical Potency Increased by up to 30-Fold: Plan to Introduce New Formulation into Ongoing Clinical Trials in Second Half of 2019 -- -- Initial Clinical Data for EDP1066 Expected Early in Third Quarter of 2019 -- -- On Track to Deliver Thu, 02 May 2019 07:00:00 -0400 Evelo Biosciences News Releases 6761 Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Thursday, May 2, 2019 http://ir.evelobio.com/news-releases/news-release-details/evelo-biosciences-host-quarterly-corporate-update-conference CAMBRIDGE, Mass. , April 25, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that it will host a conference call and live webcast Thu, 25 Apr 2019 07:30:00 -0400 Evelo Biosciences News Releases 6736 Evelo Biosciences to Present at 18th Annual Needham Healthcare Conference http://ir.evelobio.com/news-releases/news-release-details/evelo-biosciences-present-18th-annual-needham-healthcare CAMBRIDGE, Mass. , April 03, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”),  a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that management will present a corporate overview at Wed, 03 Apr 2019 08:00:00 -0400 Evelo Biosciences News Releases 6716 Evelo Biosciences to Present at 39th Annual Cowen & Co. Health Care Conference http://ir.evelobio.com/news-releases/news-release-details/evelo-biosciences-present-39th-annual-cowen-co-health-care CAMBRIDGE, Mass. , March 04, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that management will present a corporate overview at Mon, 04 Mar 2019 07:30:00 -0500 Evelo Biosciences News Releases 6706 Evelo Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights http://ir.evelobio.com/news-releases/news-release-details/evelo-biosciences-reports-fourth-quarter-and-full-year-2018 -- First Patient Dosed in University of Chicago Phase 2a Trial of EDP1503 in Metastatic Melanoma -- -- Preclinical Studies Have Shown Non-replicating Monoclonal Microbials Maintain Activity: EDP1867 in Development -- -- Initial Clinical Data for EDP1066 in Atopic Dermatitis and Psoriasis Expected Thu, 14 Feb 2019 07:00:00 -0500 Evelo Biosciences News Releases 6686 Evelo Biosciences to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 14, 2019 http://ir.evelobio.com/news-releases/news-release-details/evelo-biosciences-report-fourth-quarter-and-full-year-2018 CAMBRIDGE, Mass. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that it will host a conference call and live webcast Thu, 07 Feb 2019 08:00:00 -0500 Evelo Biosciences News Releases 6681 Evelo Biosciences Announces Dosing of First Patient in Investigator-Sponsored Phase 2a Clinical Trial of EDP1503 in Combination with KEYTRUDA® in Patients with Metastatic Melanoma http://ir.evelobio.com/news-releases/news-release-details/evelo-biosciences-announces-dosing-first-patient-investigator - Initial Clinical Data Anticipated in Second Half of 2020 - CAMBRIDGE, Mass. , Jan. 28, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a biotechnology company developing monoclonal microbials, a new modality of oral biologic medicines, today announced that the Mon, 28 Jan 2019 06:00:00 -0500 Evelo Biosciences News Releases 6671 Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications http://ir.evelobio.com/news-releases/news-release-details/evelo-biosciences-announces-dosing-first-patient-phase-12 -- Initial Clinical Data Expected in First Half of 2020 -- CAMBRIDGE, Mass. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (“Evelo”) a biotechnology company developing monoclonal microbials, a new modality of oral biologic medicines, today announced that it has dosed the Fri, 04 Jan 2019 06:00:00 -0500 Evelo Biosciences News Releases 6641